Loading quotes...
Forecast
The analysts' average price target is €9.53 (+1,021.18%). The median is €8.93 (+950.59%).
| Buy |
2 |
| Hold |
1 |
| Sell |
1 |
News Go to news feed
Tvardi presents positive phase 1 data for STAT3 inhibitor TTI-109
Tvardi reports results from a phase 1 study of TTI-109, a phosphate prodrug of TTI-101: TTI-109 converts to TTI-101 within two hours and produces similar plasma levels at molar-equivalent doses. Twenty-one days of repeated dosing showed dose-proportional pharmacokinetics and TTI-101 concentrations above the IC50 for STAT3. Pharmacodynamic data document up to a 60% reduction in STAT3-driven immune cell populations; diarrhea was shorter with TTI-109 than with TTI-101. Tvardi plans to further develop TTI-109 for dermatological and gastrointestinal indications, pending IND approval and additional funding. » More on de.investing.com
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | 100.00% |
| Net profit | -5.66m | 260.03% |
| EBITDA | -5.79m | 261.90% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €11.41m |
Number of shares | 13.34m |
52-week high/low | €5.08 - €0.69 |
| Dividends | No |
Beta | 0.36 |
P/E ratio | -0.34 |
PEG ratio | 0.01 |
P/B ratio | 1.07 |
P/S ratio | 0.00 |
Company profile
| Name | Tvardi Therapeutics |
| CEO | Imran Alibhai |
| Employees | 12 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | TVRD |
